# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN-TD
- Date: 1987-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of the new glucose plan, seen the same day by vascular surgery. **S**

## History of present illness

Ms. Fitzgerald returns two weeks after her first visit and is seen by Dr. Okafor-Lane of vascular surgery on the same day. She stopped glipizide, moved glargine 24 units to the morning, and started empagliflozin 10 mg and atorvastatin 80 mg. Her continuous glucose monitor shows glucose between 70 and 180 mg/dL 58% of the time, time below 70 mg/dL 0.5%, with a lowest reading of 68 mg/dL after a long rehearsal, and no reading below 54 mg/dL; there have been no lows after shows. She has no burning or itching with urination and no muscle aches. Calf cramping still stops her after about one and a half blocks, more on the right; she has no rest pain or sores. Her right eye remains blurred; the retina clinic will see her next week. **S**

| Element | Detail |
|---|---|
| Glucose | Time in range 58%; time below 70 mg/dL 0.5%; lowest 68 mg/dL; none below 54 |
| Medicines | Glipizide stopped; glargine 24 units each morning; empagliflozin and atorvastatin 80 mg started, no side effects |
| Claudication | Calf pain after about one and a half blocks; no rest pain |
| Eyes | Retina clinic appointment next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf cramping on walking; no chest pain, rest pain, or ankle swelling |
| Eyes | Positive | Right-eye blur unchanged |
| Genitourinary | Negative | No burning, itching, or discharge |
| Musculoskeletal | Negative | No muscle aches on the higher statin dose |
| Integumentary | Negative | No foot sores or blisters |

5 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**
- Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/70 mmHg; pulse 60 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 83.8 kg; BMI 30.8 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 83.8 kg; blood pressure 124/70, pulse 60 |
| Feet | Skin intact; calluses under the second metatarsal heads; hammer toes of the second and third toes; no ulcer; monofilament felt at all sites; feet warm with slow capillary refill on the right |
| Vascular | Femoral pulses present; popliteal and foot pulses absent on the right; foot pulses faint on the left |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes with peripheral artery disease** (E11.51). No lows below 54 mg/dL since glipizide was stopped and glargine was reduced and moved to the morning. Time in range is 58%; the usual goal is above 70%, or above 50% for an older adult at high risk of lows, and it should rise as empagliflozin takes effect. Dr. Okafor-Lane's arterial duplex shows an occluded right superficial femoral artery with flow restored above the knee and two open arteries to the foot, and a 50 to 69% narrowing of the left superficial femoral artery; no disease above the groin. She has lifestyle-limiting claudication without signs of a threatened limb, so supervised exercise and medicines come first. **S**
   - Start rivaroxaban 2.5 mg twice daily with aspirin 81 mg.
   - Supervised exercise three times a week for twelve weeks, starting next week, with a home walking plan for tour weeks.
   - No procedure now; vascular review of revascularization after twelve weeks of exercise, sooner for rest pain, a wound, or color change.
   - Podiatry appointment within three weeks.
2. **Diabetic macular edema, right eye** (E11.3311). Retina clinic appointment next week to start anti-VEGF injections. **S**
   - Keep the retina appointment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Up to date | 8.6% two weeks ago; next at three months |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 58%; time below 70 mg/dL 0.5%; none below 54 mg/dL |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No lows after shows; lowest 68 mg/dL after a long rehearsal; glucagon carried; road manager trained |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No genital symptoms; sick-day rules reviewed for travel days |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Up to date | Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L two weeks ago; next at three months |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Due | Atorvastatin raised to 80 mg two weeks ago; lipid panel due 4 to 12 weeks after the change |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; protective sensation intact; calluses and hammer toes; podiatry appointment within three weeks |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Up to date | Ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55 at intake; arterial duplex by vascular surgery today |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | Calf pain after about one and a half blocks; no rest pain |
| Referral | Vascular surgery consultation | Promptly for claudication with an abnormal ankle-brachial index | Completed today | Seen by Dr. Okafor-Lane today |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Ordered | Hospital program starts next week; home walking plan for tour weeks |
| Referral | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Ordered | Retina clinic next week for the right macular edema |
| Examination | Blood pressure | Every visit | Completed today | 124/70 mmHg, at goal below 130/80 |
| Examination | Weight and BMI | Every visit | Completed today | 83.8 kg |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | Starting today; no bleeding history; no anti-inflammatory painkillers |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Visits set around tour dates; large-print plan given; rivaroxaban cost checked with her Part D plan |

## Goal progress

- No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months. In progress; target 1987-10-26. **S**
- A1c below 7.5% by six months. In progress; target 1987-10-26. **S**
- LDL cholesterol below 55 mg/dL by six months. In progress; target 1987-10-26. **S**
- Walk at least four blocks without stopping by six months. In progress; target 1987-10-26. **S**
- No foot ulcer, and protective footwear on and off stage, through six months. In progress; target 1987-10-26. **S**

## Medication changes

- Started: Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- Supervised exercise from next week. Retina clinic next week. Podiatry within three weeks. Annual wellness visit in three weeks. Three-month review with A1c, lipids, and kidney tests. **S**
- Next scheduled visit 1987-06-15: subsequent annual wellness visit. **S**
